ARS Pharmaceuticals, Inc. revenue
ARS Pharmaceuticals, Inc.'s revenue was $84.3m in fiscal 2025, down 5.5% on the year before. Since fiscal 2021 ($5.5m) it has grown at a compound 97.8% a year. Over the last twelve months it was $117m.
Revenue history
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Products | $72.2M | 85.7% | ▲ 895.1% |
| Revenue Under Collaboration Agreements | $9.7M | 11.5% | ▼ 88.1% |
| Revenue Under Supply Agreements | $2.4M | 2.8% | ▲ 549.3% |
| Region | Revenue | Share | YoY |
|---|---|---|---|
| United States | $72.2M | 85.7% | ▲ 895.1% |
| Outside the US | $12.1M | 14.3% | ▼ 85.2% |
From ARS Pharmaceuticals, Inc.'s 10-K filed March 9, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| ARS Pharmaceuticals, Inc. | $117m | 4.1% | 711.3% |
| Arcus Biosciences, Inc. | $117m | -55.3% | -1.1% |
| Mesoblast LTD | $120m | 599.2% | — |
| Xencor Inc | $105m | -28.6% | -2.5% |
| Agenus Inc | $133m | 30.5% | 10.1% |
| Kymera Therapeutics, Inc. | $102m | 133.8% | 29.7% |
Compare with peers
- Arcus Biosciences, Inc. revenue
- Mesoblast LTD revenue
- Xencor Inc revenue
- Agenus Inc revenue
- Kymera Therapeutics, Inc. revenue
Head to head: RCUS vs SPRYMESO vs SPRYSPRY vs XNCR
More: Biotechnology stocks compared, Health Care sector, rankings of US companies